Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML.

MLA

Lo Presti, Vania, et al. “Combining CRISPR-Cas9 and TCR Exchange to Generate a Safe and Efficient Cord Blood-Derived T Cell Product for Pediatric Relapsed AML.” Journal for Immunotherapy of Cancer, vol. 12, no. 4, Apr. 2024. EBSCOhost, https://doi.org/10.1136/jitc-2023-008174.

APA

Lo Presti, V., Meringa, A., Dunnebach, E., van Velzen, A., Moreira, A. V., Stam, R. W., Kotecha, R. S., Krippner-Heidenreich, A., Heidenreich, O. T., Plantinga, M., Cornel, A., Sebestyen, Z., Kuball, J., van Til, N. P., & Nierkens, S. (2024). Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML. Journal for Immunotherapy of Cancer, 12(4). https://doi.org/10.1136/jitc-2023-008174

Chicago

Lo Presti, Vania, Angelo Meringa, Ester Dunnebach, Alice van Velzen, Aida Valera Moreira, Ronald W Stam, Rishi S Kotecha, et al. 2024. “Combining CRISPR-Cas9 and TCR Exchange to Generate a Safe and Efficient Cord Blood-Derived T Cell Product for Pediatric Relapsed AML.” Journal for Immunotherapy of Cancer 12 (4). doi:10.1136/jitc-2023-008174.